IS4261A - Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra - Google Patents

Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Info

Publication number
IS4261A
IS4261A IS4261A IS4261A IS4261A IS 4261 A IS4261 A IS 4261A IS 4261 A IS4261 A IS 4261A IS 4261 A IS4261 A IS 4261A IS 4261 A IS4261 A IS 4261A
Authority
IS
Iceland
Prior art keywords
peptides
pain
treatment
opioid
compositions
Prior art date
Application number
IS4261A
Other languages
English (en)
Inventor
Brown William
Dimaio John
Schiller Peter
Martel René
Original Assignee
Astra Aktiebolag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9403263A external-priority patent/GB9403263D0/en
Priority claimed from SE9401519A external-priority patent/SE9401519D0/xx
Application filed by Astra Aktiebolag filed Critical Astra Aktiebolag
Publication of IS4261A publication Critical patent/IS4261A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IS4261A 1994-02-21 1995-02-13 Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra IS4261A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9403263A GB9403263D0 (en) 1994-02-21 1994-02-21 Novel opiod peptides
GB9408179A GB9408179D0 (en) 1994-02-21 1994-04-25 Novel opioid peptides for the treatment of pain and use thereof
SE9401519A SE9401519D0 (sv) 1994-05-03 1994-05-03 Novel opioid peptides for the tratment of pain and use thereof

Publications (1)

Publication Number Publication Date
IS4261A true IS4261A (is) 1995-08-22

Family

ID=27267061

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4261A IS4261A (is) 1994-02-21 1995-02-13 Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra

Country Status (20)

Country Link
EP (1) EP0746567B1 (is)
JP (1) JPH09509168A (is)
AT (1) ATE217011T1 (is)
BR (1) BR9506847A (is)
CA (1) CA2181367A1 (is)
CZ (1) CZ288523B6 (is)
DE (1) DE69526577T2 (is)
EE (1) EE03265B1 (is)
ES (1) ES2176322T3 (is)
FI (1) FI963252A0 (is)
HR (1) HRP950413A2 (is)
HU (1) HUT74731A (is)
IS (1) IS4261A (is)
MX (1) MX9603489A (is)
NO (1) NO963464L (is)
NZ (1) NZ281742A (is)
PL (1) PL181092B1 (is)
SK (1) SK93596A3 (is)
TW (1) TW408131B (is)
WO (1) WO1995022557A1 (is)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9503924D0 (sv) * 1995-08-18 1995-11-07 Astra Ab Novel opioid peptides
EP0853484B1 (en) * 1995-06-07 2002-09-11 Torrey Pines Institute For Molecular Studies Novel mu opioid receptor ligands: agonists and antagonists
GB9516994D0 (en) * 1995-08-18 1995-10-18 Iaf Biochem Int Solution synthesis of peripheral acting analgestic opioid tetrapeptides
MX9709494A (es) * 1996-12-04 1998-07-31 Pfizer Compuestos peptidicos ciclicos, procedimiento para su produccion, composiciones que los contienen y uso de los mismos.
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US6548637B1 (en) 1998-06-18 2003-04-15 Sepracor, Inc. Ligands for opioid receptors
SE9900961D0 (sv) * 1999-03-16 1999-03-16 Astra Ab Novel compounds
AU2001239896A1 (en) 2000-03-16 2001-10-03 Sepracor, Inc. Peptidomimetic ligands for cellular receptors and ion channels
ATE496533T1 (de) * 2000-07-18 2011-02-15 Cornell Res Foundation Inc Medizinische verwendung von agonisten des mu- opioid rezeptors
ES2436011T3 (es) 2003-02-04 2013-12-26 Cornell Research Foundation, Inc. Métodos para prevenir la transición de la permeabilidad mitocondrial
ES2694574T3 (es) 2003-05-01 2018-12-21 Cornell Research Foundation, Inc. Método y complejos portadores para suministrar moléculas a células
CA2851972C (en) 2004-01-23 2015-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
CN101166524B (zh) 2005-04-28 2010-12-22 辉瑞有限公司 氨基酸衍生物
AU2006292352B2 (en) 2005-09-16 2012-02-09 Cornell Research Foundation, Inc. Methods for reducing CD36 expression
EP1782819A1 (en) 2005-11-03 2007-05-09 Cognis IP Management GmbH Oligopeptides and their use
US8906859B2 (en) 2006-11-10 2014-12-09 Cera Therapeutics, Inc. Uses of kappa opioid synthetic peptide amides
US8236766B2 (en) 2006-11-10 2012-08-07 Cara Therapeutics, Inc. Uses of synthetic peptide amides
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
US7713937B2 (en) 2006-11-10 2010-05-11 Cara Therapeutics, Inc. Synthetic peptide amides and dimeric forms thereof
US7402564B1 (en) 2006-11-10 2008-07-22 Cara Therapeutics, Inc. Synthetic peptide amides
CN102127152B (zh) * 2007-06-11 2012-07-04 北京大学 一种抗阿片肽的拮抗肽与该拮抗肽的应用
CN102127151B (zh) * 2007-06-11 2012-07-04 北京大学 抗阿片肽的拮抗肽与该拮抗肽的应用
CN101805396B (zh) * 2007-06-28 2011-09-14 北京大学 抗阿片肽的拮抗肽与该拮抗肽的应用
CN101817877B (zh) * 2007-06-28 2011-09-14 北京大学 一种抗阿片肽的活性片段
EP2252312B1 (en) 2008-02-07 2014-04-09 Cornell University Methods for preventing or treating insulin resistance
US8143219B2 (en) 2008-02-26 2012-03-27 Cornell University Methods for prevention and treatment of acute renal injury
EP3802560A4 (en) * 2018-05-31 2022-03-02 The University of Sydney Analgesics and methods of use thereof
JP7437578B2 (ja) * 2019-03-20 2024-02-26 国立大学法人東北大学 新規オピオイドペプチド、その糖鎖付加体及びそれらを含む医薬組成物
CN113968902B (zh) * 2020-07-25 2023-05-26 兰州大学 亮氨酸-脑啡肽类似物及其制备方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8005121A (nl) * 1979-09-20 1981-03-24 Erba Farmitalia Biologisch actieve peptiden.
DK0644772T3 (da) * 1992-11-12 2003-06-30 Sod Conseils Rech Applic Opioid-peptider
SE9300012D0 (sv) * 1993-01-05 1993-01-05 Astra Ab New peptides

Also Published As

Publication number Publication date
PL181092B1 (pl) 2001-05-31
MX9603489A (es) 1997-03-29
AU1865195A (en) 1995-09-04
HU9602281D0 (en) 1996-10-28
CZ239196A3 (en) 1996-12-11
HUT74731A (en) 1997-02-28
CA2181367A1 (en) 1995-08-24
CZ288523B6 (cs) 2001-07-11
ATE217011T1 (de) 2002-05-15
WO1995022557A1 (en) 1995-08-24
AU690648B2 (en) 1998-04-30
BR9506847A (pt) 1997-09-30
EP0746567A1 (en) 1996-12-11
NZ281742A (en) 1997-06-24
EE03265B1 (et) 2000-04-17
NO963464L (no) 1996-08-20
SK93596A3 (en) 1997-05-07
PL315947A1 (en) 1996-12-09
FI963252L (fi) 1996-08-20
ES2176322T3 (es) 2002-12-01
EP0746567B1 (en) 2002-05-02
DE69526577D1 (de) 2002-06-06
TW408131B (en) 2000-10-11
DE69526577T2 (de) 2003-01-02
HRP950413A2 (en) 1997-10-31
FI963252A7 (fi) 1996-08-20
FI963252A0 (fi) 1996-08-20
JPH09509168A (ja) 1997-09-16

Similar Documents

Publication Publication Date Title
IS4261A (is) Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
SE9503924D0 (sv) Novel opioid peptides
ATE238038T1 (de) Liposomale formulierungen von mitoxantron
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
ZA975437B (en) New pyridyl alkene and pyridyl alkine acid amides.
AP2000001785A0 (en) Medicaments
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
BRPI9708566A (pt) Análogo de glp-2, análogo de peptìdeo glp-humano, peptìdeo, composição farmacêutica, uso de um análogo de glp-2, e, processo para identificar análogos intestinotróficos de glp-2.
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
IL112111A0 (en) Peptide derivatives and pharmaceutical compositions containing them
HU9602522D0 (en) Heterocyclic compounds, their preparation and use
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
HUP0101546A2 (hu) Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
SE9902597D0 (sv) New use
EP1164141A3 (en) Opioid peptides and their use for treatment of pain
SE9502877D0 (sv) Novel opioid peptides
PT907737E (pt) Muteina da il-6
YU55095A (sh) Novi opioidni peptidi za lečenje bola i njihova primena novel
RU97112616A (ru) Лекарственный препарат для лечения проктологических заболеваний
UA22223A (uk) Спосіб лікуваhhя захворюваhь оргаhа зору